H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on Aslan Pharmaceuticals Ltd (ASLN – Research Report) today and set a price target of $8.50. The company’s shares closed on Friday at $4.13.
According to TipRanks.com, Selvaraju is ranked 0 out of 5 stars with an average return of -5.6% and a 29.6% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as Biospecifics Technologies Corp, EyePoint Pharmaceuticals Inc, and Bausch Health Companies Inc.
Aslan Pharmaceuticals Ltd has an analyst consensus of Moderate Buy, with a price target consensus of $8.50.
Based on Aslan Pharmaceuticals Ltd’s latest earnings release for the quarter ending September 30, the company reported a quarterly GAAP net loss of $11.15 million. In comparison, last year the company had a GAAP net loss of $14.51 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Aslan Pharmaceuticals Ltd. is a clinical-stage oncology-focused biopharmaceutical company, which engages in the development of novel therapeutics. Its pipeline includes varlitinib, ASLAN003, ASLAN004, and ASLAN002.